Search

Displaying results 5241 - 5250 of 10000 in total
  1. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  2. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. … Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase.

  3. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.

  4. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers. … CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms.

  5. Drug

    Iproclozide

    go.drugbank.com/drugs/DB09247
    ApprovedWithdrawn

    fatalities has resulted ultimately in the agent being discontinued. … Iproclozide is an irreversible and selective hydrazine class based monoamine oxidase inhibitor (MAOI).

  6. Drug

    TM5614

    go.drugbank.com/drugs/DB16516
    Investigational

    An animal study in mice fed a fast-food diet with TM5614 treatment showed improved metabolic measurements and reduced liver steatosis[L31673,L31678]. … Further investigation of this compound is underway, including an exploratry Phase II study for its efficacy and safety for high-risk hospitalized patients with severe COVID-19 pneumonia[L31688].

  7. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  8. Drug

    HY10275

    go.drugbank.com/drugs/DB05079
    Experimental

    HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.

  9. Drug

    ALKS 29

    go.drugbank.com/drugs/DB05723
    Experimental

    ALKS 29 is a new product candidate for the treatment of alcohol dependence. It is being developed by Alkermes, Inc.

  10. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.